Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA1890 November 2025

APPLICANT (stamp or sticker acceptable)				PATIENT NHI:	REFERRER Reg No:	
Reg No:				First Names:	First Names:	
Name:				Surname:	Surname:	
Address:				DOB:	Address:	
				Address:		
Fax Number:					Fax Number:	
Ruxolitinib						
Appli	cation	or	cation s only from a haematologist. Approvals valid for 12 months. es(tick boxes where appropriate)  The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis  A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS  A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS  and Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy  A maximum dose of 20 mg twice daily is to be given			
Renewal						
Current approval Number (if known):						
Applications only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)						
	[	The treatment remains appropriate and the patient is benefiting from treatment				
	and [		A maximum dose of 20 mg twice d	aily is to be given		

I confirm the above details are correct and that in signing this form I understand I may be audited.